MX2020002741A - Uso de gaboxadol en el tratamiento de narcolepsia. - Google Patents
Uso de gaboxadol en el tratamiento de narcolepsia.Info
- Publication number
- MX2020002741A MX2020002741A MX2020002741A MX2020002741A MX2020002741A MX 2020002741 A MX2020002741 A MX 2020002741A MX 2020002741 A MX2020002741 A MX 2020002741A MX 2020002741 A MX2020002741 A MX 2020002741A MX 2020002741 A MX2020002741 A MX 2020002741A
- Authority
- MX
- Mexico
- Prior art keywords
- narcolepsy
- gaboxadol
- treatment
- compositions
- sub
- Prior art date
Links
- 201000003631 narcolepsy Diseases 0.000 title abstract 4
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 title abstract 3
- 229950004346 gaboxadol Drugs 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000002269 analeptic agent Substances 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762557412P | 2017-09-12 | 2017-09-12 | |
| PCT/US2018/050339 WO2019055369A1 (en) | 2017-09-12 | 2018-09-11 | USE OF GABOXADOL IN THE TREATMENT OF NARCOLEPSIA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002741A true MX2020002741A (es) | 2020-07-21 |
Family
ID=65630168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002741A MX2020002741A (es) | 2017-09-12 | 2018-09-11 | Uso de gaboxadol en el tratamiento de narcolepsia. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20190076409A1 (OSRAM) |
| EP (1) | EP3661507A4 (OSRAM) |
| JP (1) | JP2020533415A (OSRAM) |
| KR (1) | KR20200053570A (OSRAM) |
| CN (1) | CN111328282A (OSRAM) |
| AU (1) | AU2018331326A1 (OSRAM) |
| CA (1) | CA3075478A1 (OSRAM) |
| IL (1) | IL272962A (OSRAM) |
| MX (1) | MX2020002741A (OSRAM) |
| WO (1) | WO2019055369A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020533415A (ja) * | 2017-09-12 | 2020-11-19 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | ナルコレプシーの処置におけるガボキサドールの使用 |
| WO2020106927A1 (en) | 2018-11-21 | 2020-05-28 | Certego Therapeutics | Gaboxadol for reducing risk of suicide and rapid relief of depression |
| WO2020259787A1 (en) | 2019-06-28 | 2020-12-30 | University Of Copenhagen | Treatment of cns disorders with sleep disturbances |
| MX2022014599A (es) | 2020-05-20 | 2022-12-16 | Certego Therapeutics Inc | Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos. |
| US20250375429A1 (en) | 2024-05-29 | 2025-12-11 | Smarter Not Harder, Inc. | Obligate pairing of orthosteric and non-orthosteric gaba ligands in pharmaceutical formulations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200528098A (en) * | 2003-12-18 | 2005-09-01 | Lundbeck & Co As H | Treatment of insomnia in human patients |
| US20050215521A1 (en) * | 2003-12-22 | 2005-09-29 | Karim Lalji | Modafinil combination therapy for improving sleep quality |
| US9480695B2 (en) * | 2011-09-29 | 2016-11-01 | The University Of Tokyo | Methods for inducing orexin neurons and agent for treating narcolepsy or eating disorder |
| US9050302B2 (en) * | 2013-03-01 | 2015-06-09 | Jazz Pharmaceuticals Ireland Limited | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
| US9359290B2 (en) * | 2013-03-13 | 2016-06-07 | Jazz Pharmaceuticals International Iii Limited | Treatment of cataplexy |
| US9682069B2 (en) * | 2015-07-17 | 2017-06-20 | Ovid Therapeutics Inc | Methods of treating Dravet syndrome |
| CN109414435A (zh) * | 2016-05-26 | 2019-03-01 | 奥维德医疗公司 | 使用哌苯甲醇治疗行为综合征的方法 |
| JP2020533415A (ja) * | 2017-09-12 | 2020-11-19 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | ナルコレプシーの処置におけるガボキサドールの使用 |
-
2018
- 2018-09-11 JP JP2020536720A patent/JP2020533415A/ja active Pending
- 2018-09-11 EP EP18856943.8A patent/EP3661507A4/en not_active Withdrawn
- 2018-09-11 US US16/127,375 patent/US20190076409A1/en not_active Abandoned
- 2018-09-11 MX MX2020002741A patent/MX2020002741A/es unknown
- 2018-09-11 CA CA3075478A patent/CA3075478A1/en active Pending
- 2018-09-11 CN CN201880072667.9A patent/CN111328282A/zh active Pending
- 2018-09-11 KR KR1020207010674A patent/KR20200053570A/ko not_active Withdrawn
- 2018-09-11 AU AU2018331326A patent/AU2018331326A1/en not_active Abandoned
- 2018-09-11 WO PCT/US2018/050339 patent/WO2019055369A1/en not_active Ceased
-
2020
- 2020-02-27 IL IL272962A patent/IL272962A/en unknown
- 2020-03-25 US US16/829,423 patent/US20200222372A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN111328282A (zh) | 2020-06-23 |
| WO2019055369A1 (en) | 2019-03-21 |
| US20190076409A1 (en) | 2019-03-14 |
| KR20200053570A (ko) | 2020-05-18 |
| EP3661507A1 (en) | 2020-06-10 |
| JP2020533415A (ja) | 2020-11-19 |
| IL272962A (en) | 2020-04-30 |
| EP3661507A4 (en) | 2020-11-18 |
| CA3075478A1 (en) | 2019-03-21 |
| AU2018331326A1 (en) | 2020-03-19 |
| US20200222372A1 (en) | 2020-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| MX2021004708A (es) | Metodos y composiciones para tratamiento de presbicia, midriasis y otros trastornos oculares. | |
| MX2022007989A (es) | Composiciones y metodos para tratar pterigion. | |
| CR20200064A (es) | Carboxamidas como moduladores de los canales de sodio | |
| EA201791882A1 (ru) | Агонисты 5ht для лечения нарушений | |
| MY182454A (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
| JOP20200230B1 (ar) | ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها | |
| MX389702B (es) | Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+). | |
| PE20190338A1 (es) | Metodos de tratamiento de trastornos del desarrollo con gaboxadol | |
| HK1245078A1 (zh) | 治疗神经退行性疾病的方法 | |
| TW201713341A (en) | Compositions and methods of treating a neurodegenerative disease | |
| GEP20247585B (en) | Furoindazole derivatives | |
| AU2015267099A8 (en) | Use of eribulin in the treatment of cancer | |
| TW201613578A (en) | Pharmaceutical combinations | |
| PH12021550671A1 (en) | Prodrugs of cgrp antagonists | |
| WO2016168553A8 (en) | Deuterated obeticholic acid | |
| PL3348547T3 (pl) | Pochodne benzimidazolu jako inhibitory NAV 1.7 (kanał sodowy, bramkowany napięciem, typ IX, podjednostka alfa (SCN9A)) do leczenia bólu, dysurii i stwardnienia rozsianego | |
| PH12020500542A1 (en) | Dopamine-b-hydroxylase inhibitors | |
| MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
| MX2017009110A (es) | Terapia de combinacion para hipertension pulmonar. | |
| MX2019007041A (es) | Metodos y composiciones para tratar la enfermedad de parkinson. | |
| EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| MX2023012415A (es) | Metodos de uso del dantroleno para tratar la exposicion a agente nervioso. | |
| EA201892583A1 (ru) | Комбинация чистых антагонистов 5-htрецептора с антагонистом nmda рецептора |